ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort

The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non‐small cell lung cancer: A meta‐analysis

“…Osimertinib has been demonstrated to significantly increase the PFS and OS compared with treatment with pemetrexed plus platinum in the AURA3 study (NCT02151981), 37 with a PFS of 10.1 months. The clinical efficacy and safety of Osimertinib in diverse populations have also been reported in the ASTRIS study (NCT02474355), 38–42 which examined data from South Korea, Spain, Belgium, and other nations. The PFS and OS of the above studies were similar to the results of the articles included in the meta‐analysis.…”

“… 67 In the current study, we carried out a subgroup analysis based on the ethnicity of the population and confirmed that Asian patients treated with Osimertinib had a similar HR to non‐Asian patients in the T790M‐maintenance group compared with the T790M‐loss group, indicating that the clinical benefits of Osimertinib in the Asian and non‐Asians population were higher both in terms of incidence probability and treatment effect, which are comparable to the findings of earlier investigations. 37 , 38 , 39 , 40 , 41 , 49 , 64 However, in the current analysis, most of the studies in the Asian populations were single‐center trials carried out by Chinese and Korean research organizations, while only one study in non‐Asian populations were included. Thus, further studies are required to validate our findings.…”